{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-012028","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.151590+00:00","generated_at":"2026-06-13T05:34:19.944998+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Coherus appoints Michael Ryan to board of directors","bullets":["Michael Ryan appointed to Coherus board effective July 18, 2023; fills Class III vacancy until 2026 annual meeting.","Ryan has 40 years in biopharma; most recently SVP at Bristol-Myers Squibb and earlier VP at Amgen.","Compensation: annual cash retainer of $50,000; initial option for 54,000 shares vesting monthly over 3 years.","Also founder/CEO of Koios Enterprises, an executive consulting firm focusing on patient access."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-012028","json":"https://secwatch.observer/filing/0001558370-23-012028.json","markdown":"https://secwatch.observer/filing/0001558370-23-012028.md","text":"https://secwatch.observer/filing/0001558370-23-012028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023012028/0001558370-23-012028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023012028/chrs-20230718x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:34:19.944998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efeecbe4a4","claim":"Michael Ryan was appointed as Class III director at Coherus Oncology, Inc..","evidence_excerpt":"On July 18, 2023, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Michael Ryan, Pharm.D., to serve as a Class III director to fill a vacancy on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023012028/0001558370-23-012028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}